Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jun;85(2):541–546. doi: 10.1111/j.1476-5381.1985.tb08891.x

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

J P Finberg, M B Youdim
PMCID: PMC1916611  PMID: 3928010

Abstract

The selective monoamine oxidase (MAO) inhibitors clorgyline, selegiline and AGN 1135 did not cause a change in responses of the cat nictitating membrane to preganglionic sympathetic nerve stimulation at 5 Hz. Both selective MAO-A and MAO-B inhibitors markedly potentiated nictitating membrane contractions in response to beta-phenylethylamine (PEA). However, the responses to tyramine were unchanged. The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors. At the doses used selegiline and AGN 1135 caused a near total selective inhibition of liver and brain MAO-B, while clorgyline inhibited MAO-A only in the brain. AGN 1135, like selegiline, could be a useful drug in potentiating the action of L-DOPA in Parkinson's disease.

Full text

PDF
541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkmayer W., Riederer P., Ambrozi L., Youdim M. B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977 Feb 26;1(8009):439–443. doi: 10.1016/s0140-6736(77)91940-7. [DOI] [PubMed] [Google Scholar]
  2. Coquil J. F., Goridis C., Mack G., Neff N. H. Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br J Pharmacol. 1973 Aug;48(4):590–599. doi: 10.1111/j.1476-5381.1973.tb08245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Elsworth J. D., Glover V., Reynolds G. P., Sandler M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978 Apr 14;57(1):33–38. doi: 10.1007/BF00426954. [DOI] [PubMed] [Google Scholar]
  4. Finberg J. P., Tenne M., Youdim M. B. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981 May;73(1):65–74. doi: 10.1111/j.1476-5381.1981.tb16772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fowler C. J., Tipton K. F. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol. 1981 Dec 15;30(24):3329–3332. doi: 10.1016/0006-2952(81)90607-9. [DOI] [PubMed] [Google Scholar]
  6. Fowler C. J., Tipton K. F. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem. 1982 Mar;38(3):733–736. doi: 10.1111/j.1471-4159.1982.tb08692.x. [DOI] [PubMed] [Google Scholar]
  7. Garcha G., Imrie P. R., Marley E., Thomas D. V. Effects of monoamine oxidase inhibitor (MAOI) pretreatment on the fate of intraduodenally instilled [14C]-tyramine [proceedings]. Br J Pharmacol. 1979 Nov;67(3):454P–455P. [PMC free article] [PubMed] [Google Scholar]
  8. Glover V., Pycock C. J., Sandler M. Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl. Br J Pharmacol. 1983 Sep;80(1):141–148. doi: 10.1111/j.1476-5381.1983.tb11059.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Green A. R., Youdim M. B. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975 Nov;55(3):415–422. doi: 10.1111/j.1476-5381.1975.tb06946.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jarrott B. Occurrence and properties of monoamine oxidase in adrenergic neurons. J Neurochem. 1971 Jan;18(1):7–16. doi: 10.1111/j.1471-4159.1971.tb00162.x. [DOI] [PubMed] [Google Scholar]
  11. Kalir A., Sabbagh A., Youdim M. B. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981 May;73(1):55–64. doi: 10.1111/j.1476-5381.1981.tb16771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  13. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177–198. doi: 10.1007/BF01246955. [DOI] [PubMed] [Google Scholar]
  14. Lader M. H., Sakalis G., Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia. 1970 Aug 19;18(1):118–123. doi: 10.1007/BF00402391. [DOI] [PubMed] [Google Scholar]
  15. Richardson J. B., Dixon M. Varicose veins in tropical Africa. Lancet. 1977 Apr 9;1(8015):791–792. doi: 10.1016/s0140-6736(77)92971-3. [DOI] [PubMed] [Google Scholar]
  16. Sandler M., Glover V., Ashford A., Stern G. M. Absence of "cheese effect" during deprenyl therapy: some recent studies. J Neural Transm. 1978;43(3-4):209–215. doi: 10.1007/BF01246957. [DOI] [PubMed] [Google Scholar]
  17. Simpson L. L. Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol. 1978;27(11):1591–1595. doi: 10.1016/0006-2952(78)90490-2. [DOI] [PubMed] [Google Scholar]
  18. Squires R. F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol. 1972;5:355–370. [PubMed] [Google Scholar]
  19. Youdim M. B. In vivo, noradrenaline is a substrate for rat brain monoamine oxidase A and B. Br J Pharmacol. 1983 Jun;79(2):477–480. doi: 10.1111/j.1476-5381.1983.tb11021.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES